Octreotide-¹³C₉，¹⁵N  (Synonyms: SMS 201-995-¹³C₉，¹⁵N)

Octreotide-¹³C₉,¹⁵N (SMS 201-995-¹³C₉,¹⁵N) is ¹³C and ¹⁵N labeled Octreotide. Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly^[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1029.17

C₄₀¹³C₉H₆₆N₉¹⁵NO₁₀S₂

83150-76-9

O=[13C](N[C@@H]1CC2=CNC3=CC=CC=C23)[13C@H]([13CH2][13C]4=[13CH][13CH]=[13CH][13CH]=[13CH]4)[15NH]C([C@@H](NC([C@@H](CC5=CC=CC=C5)N)=O)CSSC[C@@H](C(N[C@@H]([C@@H](C)O)CO)=O)NC([C@]([H])([C@@H](C)O)NC([C@H](CCCCN)NC1=O)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]